Fatty acid synthase (FASN), the enzyme that catalyzes de novo synthesis of fatty acids, is expressed in many cancer types. Its potential as a therapeutic target is well recognized, but inhibitors of FASN have not yet been approved for cancer therapy. Orlistat (ORL), an FDA-approved lipase inhibitor, is also an effective inhibitor of FASN. However, ORL is extremely hydrophobic and has low systemic uptake after oral administration. Thus, new strategies are required to formulate ORL for cancer treatment as a FASN inhibitor. Here, we report the development of a nanoparticle (NP) formulation of ORL using amphiphilic bioconjugates that are derived from hyaluronic acid (HA), termed Nano-ORL. The NPs were loaded with up to 20 wt% weight of ORL at greater than 95% efficiency. The direct inhibition of the human recombinant thioesterase domain of FASN by ORL extracted from Nano-ORL was similar to that of stock ORL. Nano-ORL demonstrated a similar ability to inhibit cellular FASN activity when compared to free ORL, as demonstrated by analysis of 14 C-acetate incorporation into lipids. Nano-ORL treatment also disrupted mitochondrial function similar to ORL by reducing adenosine triphosphate turnover in MDA-MB-231 and LNCaP cells. Nano-ORL demonstrated increased potency compared to from ORL towards prostate and breast cancer cells. Nano-ORL decreased viability of human prostate and breast cancer cell lines to 55 and 57%, respectively, while free ORL decreased viability to 71 and 79% in the same cell lines. Moreover, Nano-ORL retained cytotoxic activity after a 24 h pre-incubation in aqueous conditions. Pre-incubation of ORL dramatically reduced 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 3 the efficacy of ORL as indicated by high cell viability (>85%) in both breast and prostate cell lines. These data demonstrate that NP formulation of ORL using HA-derived polymers retains similar levels of FASN, lipid synthesis, and ATP turnover inhibition while significantly improving the cytotoxic activity against cancer cell lines.
Introduction
Nearly all cancers show increased endogenous fatty acid synthesis, regardless of the level of circulating dietary fatty acids. 1 The key enzyme responsible for this process is homodimeric and multifunctional, fatty acid synthase (FASN), which cyclically produces fatty acids, using malonyl-CoA, acetyl-CoA, and NADPH. 2 The primary product of FASN is the 16-carbon fatty acid palmitate. In healthy liver and other lipogenic tissues, palmitate is produced primarily to store excess energy in the form of triglycerides, and is regulated by dietary intake. 1,3 However, the activity of FASN and the fate of palmitate is quite different in cancerous tissue, where palmitate is primarily synthesized into phospholipids, the predominant class of lipids found in cell membranes, and regulation is typically independent of circulating fatty acids. 1, 3 Evidence has accumulated that FASN confers a survival advantage to cancers and their precursor lesions, indicating its status as a potential metabolic oncogene. 1,4,5 Increased FASN expression has been shown in every major cancer type and it has been recognized as a potential target for therapy. 3, 5 Several molecules that target FASN have been investigated, including cerulenin, C75, epigallocatechin-3-gallate, and triclosan, 6-9 but these have off-target effects and unwanted side effects. 3, 8 Thus, new molecules and formulations are needed that cause fewer side effects.
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Orlistat (ORL) is an FDA approved weight loss drug, which, when taken orally, inhibits gastric and pancreatic lipases. 10 In addition to lipase activity, ORL has been shown to be a potent inhibitor of FASN, where ORL binds to the thioesterase domain of the enzyme, leading to the hydrolysis of the β-lactone group within ORL. [11] [12] [13] In cellular assays, ORL effectively inhibits FASN, reduces cancer cell and endothelial cell proliferation, and reduces angiogenesis. [13] [14] [15] Mechanisms associated with this include, cell cycle blockade, ER stress, and apoptosis. [16] [17] [18] In vivo tumor models have shown that ORL reduces tumor growth, metastasis, and angiogenesis, but at very high ORL concentrations. [19] [20] [21] [22] ORL is extremely hydrophobic ( Figure 1 ); its predicted logP is 8.1.
23, 24 Less than 2.5% of ORL is absorbed after oral administration of which, approximately 42% of ORL is degraded into two metabolites. 10, 25 Due to the high hydrophobicity, low absorption, and poor metabolic stability, a means of improving delivery of ORL to tumors is needed.
In order to facilitate delivery of active ORL to tumor cells we have developed a novel ORL formulation, termed Nano-ORL, in which ORL is loaded into the hydrophobic regions of self-assembled polymeric nanoparticles (NPs) derived from hyaluronic acid (HA) (Figure 1 ). HA is a hydrophilic, extracellular glycosaminoglycan composed of repeating units of β(1,4) D-glucuronic acid and β(1,3) N-acetyl-Dglucosamine. 26, 27 Polymeric NPs utilizing HA as the hydrophilic backbone have previously been shown to improve delivery of drugs and imaging agents to tumors. [28] [29] [30] We have previously synthesized HA-derived NPs using the hydrophobic conjugate aminopropyl-1-pyrenebutanamide (PBA), which efficiently loaded indocyanine green and improved its delivery to tumors. 28 In this study we now utilize these polymer 5 conjugates to instead load ORL to form Nano-ORL as depicted in Figure 1 . Nano-ORL was analyzed for physicochemical properties and ORL loading capability, FASN-TE domain inhibition, 14 C-acetate incorporation in cancer cell lines, cytotoxicity human prostate and breast cell lines, and metabolic analysis. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Synthesis of Amphiphilic HA
Synthesis of PBA and conjugation to HA was performed as described previously. 28 Briefly, 1-pyrenebutyric acid (1.0 g, 3.5 mmol) was dissolved in methanol and refluxed at 65 °C for 6 h. 1-pyrenebutyric methyl ester was then isolated and refluxed in 1,3-diaminopropane at 130 °C for 6 h. The product, PBA, was then precipitated with cold water and washed with cold water using vacuum filtration, followed by drying in a vacuum desiccator. Conjugation of PBA to HA was then performed by separately dissolving PBA (10 mg, 29 µmol) in 25 ml DMF, and HA (90 mg) in 25 ml H 2 O. 0.8 mmol EDC and NHS were then added to the HA solution, and the PBA was added dropwise under constant stirring. The reaction was allowed to proceed for 24 h. This was followed by dialysis into 50:50 H 2 O:EtOH for 24 h, dialysis into pure H 2 O for 48 h, then lyophilization.
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Preparation of Nano-ORL ORL was isolated from Xenical capsules by mixing capsule contents into 10 ml EtOH, followed by vortexing and centrifugation at 1500 RPM for 5 minutes. Supernatant containing ORL was removed from the precipitated filler material, followed by a second separation and centrifugation. Stock 12 mg/ml (24.2 mM) ORL solution was then aliquoted and stored at -20 °C. Alternatively, stock solution was also prepared from powdered ORL (Alfa Aesar) by dissolution into ethanol or methanol to a concentration of 12 mg/ml followed by storage at -20 °C. ORL was loaded into NPs by dissolution of 18.0 mg HA into 10 ml H 2 O, followed by addition of 10 ml ethanol. ORL (2.0 mg, 4.0 µmol, 20wt% loading) was then added and the solution was dialyzed against pure water for 24
h. Material was then filtered through PD-10 columns (GE Lifesciences; Pittsburgh, PA)
to remove free ORL, followed by lyophilization and storage at -20 °C. This material is termed Nano-ORL. Empty NPs formed via self-assembly upon dissolution in aqueous solution, as described previously.
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ORL loading efficiency was determined by extraction from Nano-ORL followed by HPLC quantification. Extraction of ORL was performed following the protocol for extraction of ORL from human plasma as described in the literature. 31 A standard curve of ORL extraction from NPs was obtained by spiking solutions of empty NPs with known quantities of ORL from stock solution and performing the following extraction protocol.
Empty NPs were dissolved into pure H 2 O to a concentration of 1.0, 0.5, or 0.25 mg/ml.
Stock ORL was then added to the empty NP solutions to a concentration of 0.20, 0.10, or 0.05. mg/ml. 1.0 ml aliquots of these solutions were then mixed with 1.0 ml acetonitrile, to which 5 ml n-hexane was added. This solution was then stirred for 30 minutes, at 
Physicochemical characterization
5 wt%, 10 wt%, and 20 wt% Nano-ORL formulations were synthesized in order to test the effect of ORL loading on NP size and zeta-potential. 0 wt% (empty NPs), 5 wt%, 10 wt%, and 20 wt% ORL formulations were dissolved in pure H 2 O to a concentration of 1.0 mg/ml. Hydrodynamic diameter was then determined using a ZetaPlus system with onboard dynamic light scattering (DLS) analyzer (Brookhaven Instruments Corporation; Holtsville, NY). Zeta potential was determined using a Zetasizer Nano ZS90 (Malvern Instruments; Worcestershire, UK).
Inhibition of FASN and lipid synthesis
The C-terminal thioesterase domain of FASN (FASN-TE, residues 2200-2510) was expressed and purified as previously reported. 11 The inhibition assay using 4- 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 incubate at 37 °C for 48 h. After 48 h incubation, cells were analyzed by CCK-8 assay (Dojindo, Japan) and results were normalized to the standard media group.
Similar methods were used to study the effect of pre-incubation on ORL and Nano-ORL. ORL and Nano-ORL were first dissolved in serum-free media at concentrations of 0.124 mg/ml (250 µM) and 0.62 mg/ml, respectively. These solutions were then incubated for 24 h at 37 °C. ORL and Nano-ORL solutions were then diluted to 0.0124 mg/ml (25 µM) and 0.062 mg/ml, respectively, in serum-containing media.
Empty NPs were treated in a manner identical to Nano-ORL. Non-incubated ORL and Nano-ORL solutions were also formed at identical concentrations to pre-incubated ORL and Nano-ORL. All non-incubated solutions, including standard media, were diluted to the same FBS and penicillin/streptomycin concentrations as pre-incubated solutions.
Solutions were then applied to PC-3, LNCaP, or MDA-MB-231 cancer cell lines in 96-well plates and allowed to incubate for 24 h. At 24 h, solutions were re-applied (both preincubated and non-incubated) in order to maintain concentrations of free ORL and Nano-ORL. CCK-8 assay was performed at 48 h and all groups were normalized to the standard media group.
Cellular recovery after exposure to ORL formulations
Cells were seeded at 1×10 3 cells per well (PC-3, LNCaP) or 3×10 3 cells per well (MDA-MB-231) in 96 well plates. Cells were allowed to adhere for 24 h prior to treatment with test formulations. After 24 h, treatment media was removed and replaced with fresh media without ORL or Nano-ORL. Cells were allowed to recover from treatment for 24 h before 20 μl CellTiter 96 AQ ueous One reagent was added to each well. 
Mitochondrial function assays and bioenergetics measurement
All cellular oxygen consumption rates (OCR) were measured using the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 12 accordance with published Seahorse protocols and previous publications 36 to analyze results:
Immediately post-assay, cells from each treatment group were collected, counted, and viability determined by trypan blue exclusion. Basal OCR levels were normalized to average number of live cells per well.
Statistical Analysis
All statistical analyses were performed with GraphPad Prism 6.0 software (San Diego, CA). Extracted stock ORL measured by HPLC was plotted and analyzed using linear regression to form a standard curve. Extracted Nano-ORL was quantified using this 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 13 standard curve. Average hydrodynamic diameters and zeta-potential of Nano-ORL with different loading wt% ORL were plotted and analyzed using linear regression. FASN inhibition, 14 C-acetate incorporation, cytotoxicity, cellular recovery, and mitochondrial respiration assays were analyzed separately using two-way ANOVA with multiple comparisons using Tukey's post-test.
Results
Drug loading and physical characterization
Supplementary Figure 1 shows the standard curve and extracted Nano-ORL
values. An R 2 = 0.98 was achieved over the range from 0.05 mg/ml to 0.20 mg/ml.
Analysis of the extracted Nano-ORL demonstrated a loaded wt% of 19.3 wt% ± 0.4wt%, corresponding to a 96.7% ± 2.4% loading efficiency. The effect of ORL loading on NP size was determined by loading 0, 5, 10, and 20 wt% ORL. Figure 2A shows the linear effect that ORL has on Nano-ORL effective diameter (R 2 = 0.99) indicating that ORL loading has a direct influence on the size of Nano-ORL, with hydrodynamic diameters ranging from approximately 290 (± 7) -580 (± 13) nm, from 0 wt% ORL to 20 wt% ORL, respectively. Dispersity, as measured by DLS, ranged from 0.09 (10 wt% ORL) to 0.2 (0 wt% ORL), and did not depend on ORL content. Zeta-potential of Nano-ORL formulations ranged from -27 to -35 mV and did not correlate with ORL content, ( Figure   2B ). 
Inhibition of FASN and fatty acid synthesis
To determine that Nano-ORL remained able to inhibit FASN, ORL was extracted
from Nano-ORL and tested for inhibition of FASN-TE to ensure that Nano-ORL retained the same molecular action as free ORL ( Figure 3A) . At 10 μM, extracted stock ORL inhibited 93.1% ± 5.4% of FASN-TE activity and extracted Nano-ORL inhibited 93.4% ± 6.4% of FASN-TE activity. At 1 µM and 0.1 µM, extracted stock ORL and Nano-ORL 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 60
Effect on Cell Viability
The cytotoxicity of Nano-ORL was next tested against human cancer cell lines.
As seen in Figure 4 (A-C) both ORL and Nano-ORL significantly reduced cell viability.
In PC-3 and LNCaP prostate cancer cell lines, Nano-ORL reduced cell viability to 54%
and 31%, respectively, while ORL reduced viability to 71% and 51% respectively.
Similarly, Nano-ORL reduced MDA-MB-231 viability to 57% while ORL reduced viability to 79%. These differences between Nano-ORL and ORL were statistically significant (p ≤ 0.0001) and indicate that NP formulations of ORL increase toxicity by an additional 24%, 39%, and 28% for PC3, LNCaP, and MDA-MB-231 cells, respectively.
In LNCaP cells, empty NPs decreased viability by 15% relative to untreated cells (p ≤
0.0001).
To test the duration of Nano-ORL activity compared to free ORL, ORL, Nano-ORL, and empty NPs were pre-incubated for 24 h at 37 °C prior to application to cells (designated with PI superscript). Media was re-applied at 24 h (after an additional 24 h pre-incubation) to ensure a consistent level of pre-incubated drugs and materials, and plates were tested after a total of 48 h exposure. The data in Figure 4 (D-F) indicate that ORL and Nano-ORL are cytotoxic without pre-incubation, although Nano-ORL was significantly more toxic than ORL (p ≤ 0.0001 for MDA-MB-231, p ≤ 0.01 for LNCaP, and p ≤ 0.01 for PC-3). Interestingly, when NanoORL and ORL were pre-incubated for 24 h in media, Nano-ORL provided a formulation where cytotoxicity was maintained under these harsher conditions, while free ORL had little potency under these same conditions (86%, 105%, and 95% viability in PC-3, LNCaP, and MDA-MB-231 cells, respectively; p ≤ 0.0001 compared to cells treated with ORL and no pre-incubation). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 19 incubated Nano-ORL exhibited higher toxicities than free ORL. ****: p ≤ 0.0001; NS = not significant.
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Mitochondrial Stress Analysis
Discussion
Previous studies have demonstrated that ORL inhibits FASN, triggers apoptosis, and inhibits tumor growth, metastasis, and angiogenesis. 13, 21, 22 A growing body of evidence suggests that reliance on FASN in cancer is nearly ubiquitous and thus presents a valuable target for therapy. 1,3,5 Indeed, ORL has been used in pre-clinical investigations against several cancer types, including prostate, gastric, oral, skin, and leukemia. 13, [19] [20] [21] 37 In combination, the low bioavailability through enteric delivery, high degree of hydrophobicity, and potential for off-target effects present significant barriers to clinical use of ORL and require novel developments in new ORL formulations. 10, [23] [24] [25] In our previous work, we demonstrated that HA modified with PBA could entrap the near infrared fluorophore indocyanine green and preferentially delivery the dye to 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   24 tumors. 28 We postulated that the PBA modified HA polymers could load ORL through self-assembly of the amphiphilic polymeric bioconjugate resulting in a new ORL formulation (Figure 1) . ORL, as demonstrated here, is effectively loaded into the amphiphilic HA NPs. The high loading efficiency observed with Nano-ORL (96.7% ± 2.4%) shows a strong association between ORL and the NPs, likely through interaction with hydrophobic domains created by PBA. 28 Since NP biodistribution is dependent on diameter, the ability to control NP size based on ORL content could prove useful in optimizing biodistribution, circulation time, and delivery of Nano-ORL to tumors.
The direct inhibition of FASN and decreased lipid synthesis (Figure 3) demonstrate that Nano-ORL has the same molecular activity as free ORL. Nano-ORL had similar FASN-TE inhibition compared to free ORL ( Figure 3A ). This strongly indicates that the molecular action of Nano-ORL retains the same FASN inhibitory activity as free ORL. Inhibition of cellular lipid synthesis, as indicated by 14 C-acetate incorporation, was also similar between free ORL and Nano-ORL, further demonstrating that Nano-ORL retains the molecular action of free ORL and that Nano-ORL effectively inhibits new lipid synthesis in cancer cells.
Analysis of the cytotoxic effect of Nano-ORL against prostate (PC-3 and LNCaP)
and breast (MDA-MB-231) cancer cell lines demonstrated the improved efficacy of the Nano-ORL formulation over free ORL (Figure 4) . 48-h cytotoxicity analysis resulted in higher levels of toxicity from Nano-ORL as compared to free ORL ( Figure 4A ). The increase in cytotoxicity of Nano-ORL may result from increased solubility of ORL due to its entrapment within NPs, which could result in a higher availability. It is also possible that Nano-ORL experiences greater internalization due to binding with HA, which can be 25 endocytosed and subsequently delivery therapeutics intracellularly. 38 In order to show that Nano-ORL retains its activity longer than free ORL, both ORL and Nano-ORL were pre-incubated for 24 h prior to exposure to cells ( Figure 4B ). This period allowed for a number of processes to potentially occur, including self-association and aggregation, Interestingly, inhibition of lipid synthesis was not observed to be different over the 18 h incubation when cells were treated with either pre-incubated or non-preincubated ORL or Nano-ORL formulations (SF 2). While this appears to be in contrast to the increased relative viability of cells when treated with pre-incubated free ORL, the 18 h time point was chosen specifically to avoid complicating cytotoxic effects, thereby uncoupling the effects of cytotoxicity and lipid synthesis inhibition. Detailed metabolic analysis also shows that Nano-ORL decreases basal respiration and coupling efficiency equal to, or better than, free ORL ( Figure 6 ). This indicates that both the total O 2 26 consumed, and ATP turnover, respectively, are reduced in cells treated with Nano-ORL or free ORL. Thus, both ORL and Nano-ORL exhibit a combination of reduced lipid synthesis and mitochondrial metabolism, which results in a cytotoxic effect against cancer cell lines. Nano-ORL, however, shows superior stability and solubility in aqueous solution, which results in higher cytotoxicity over extended periods of time. Overall, these results show that Nano-ORL has the same molecular action as free ORL, but provides improved bioavailability due to the soluble, amphiphilic HA-NP formulation.
The Nano-ORL NPs developed here ranged from 400 nm (average HD) with 5 wt% ORL loading to 580 nm (average HD) with 20 wt% ORL loaded. While these NPs may be outside the optimal biodistribution size range, we believe they are nevertheless viable candidates to deliver ORL to tumors. Bae and Park 39 and Petros and DeSimone 40 report that 500 nm is the approximate maximum diameter for particles to be capable of utilizing the EPR effect, and 200-500 nm to avoid clearance by the spleen. Therefore, Nano-ORL formulations with lower ORL loading would fit into the optimized size regime for the EPR effect. Future studies aimed at determining the biodistribution of this and next generation Nano-ORL formulations, which identify strategies to maintain Orl loading while tuning NP size are required. Specific strategies will include reducing Nano-ORL size either mechanically, e.g. using filtration, and/or chemically, such as using lower molecular weight polymers and conjugating alternative hydrophobic ligands to improve ORL packing within NPs. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 27 ORL demonstrated improved cytotoxic activity against human prostate and breast cancer cell lines over free ORL and reduced the metabolic activity and recovery of treated cells.
These results show the potential of NP formulations of ORL and warrant continued investigation of Nano-ORL as a therapeutic. A comprehensive evaluation of Nano-ORL treatment of tumors in vivo is currently underway, which will include next-generation of Nano-ORL formulations. The study will evaluate Nano-ORL dosing amount and frequency, relationship between ORL loading (high vs. low) and toxicity, Nano-ORL composed of varying HA molecular weight, different hydrophobic moieties structurally optimized to be more efficiently loaded with ORL, dye-labeled HA to longitudinally track NP components, and key toxicological outcomes.
Acknowledgments
This work was supported in part by the National Institutes of Health grants R00 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 59 60 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 60 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
ACS Paragon Plus Environment Molecular Pharmaceutics
